The cost of a popular Vertex Pharmaceuticals therapy could be contributing to cystic fibrosis (CF) treatment disparities around the world, researchers argued in a recent paper. Just 12% of some ...
I was living on the precipice of end-stage disease when I enrolled in the clinical trial that resulted in the historically fast Food and Drug Administration approval for the game-changing cystic ...
Getting your Trinity Audio player ready... Colorado’s new prescription drug review board decided in a first-in-the-nation vote that a medication costing more than $200,000 a year doesn’t qualify as ...
Add Yahoo as a preferred source to see more of our stories on Google. Positive Trikafta results set a benchmark of efficacy for future CF therapies. Photo by filadendron/E+ via Getty Images. On 18 May ...
Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor ...
-Interim results of largest real-world study of TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) showed sustained improvement in lung function, reduction ...
Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising ...
The company has a 97% market share in the cystic fibrosis market with a forecasted 35% revenue growth in Trikafta drug in 2021. We expect its long-term growth to be driven by diversification to other ...
Credit: Vertex. A new oral granule formulation has been approved and is supplied in morning and evening unit-dose packets. The approval was based on data from a 24-week open-label, two-part phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results